-
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)
| 17 December 2009 |
At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders).
-
Decision on future reimbursement status of medicinal products in ATC groups A04 and A03FA
| 01 December 2009 |
On 25 November 2009, the Danish Medicines Agency made a decision on the future reimbursement status of medicinal products in ATC group A04 (antiemetics and antinauseants) and medical products in ATC group A03FA (propulsives)
-
Decision on future reimbursement status for medicinal products in ATC group C04 (peripheral vasodilators)
| 05 October 2009 |
On 21 September 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group (peripheral vasodilators).
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)
| 02 October 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C05 (Vasoprotectives).
-
Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)
| 08 September 2009 |
On 3 september 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds).
-
Decision on the future reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)
| 04 August 2009 |
On 3 July 2009, the Danish Medicines Agency made a decision on the future reimbursement status of medicinal products in ATC group A08 (antiobesity preparations excl. diet products).
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C04 (Peripheral vasodilators)
| 30 June 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C04 (Peripheral vasodilators)
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)
| 30 June 2009 |
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives).
-
Changes in reimbursement for cardiovascular medicine as of 13 July 2009
| 09 June 2009 |
The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of cardiovascular disease (‘antihypertensives’) in order to assess whether they meet the
-
Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation
| 04 June 2009 |
The Reimbursement Committee's recommendation on the future reimbursement status of laxatives (ATC groups A06 and A02AA04) has been open for consultation until 27 May 2009.
-
Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation
| 04 June 2009 |
The Reimbursement Committee's recommendation on the future reimbursement status of antiobesity preparations, excl. diet products (ATC group A08) has been open for consultation until 25 May 2009.
-
Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
| 04 May 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
-
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)
| 30 April 2009 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).
-
Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09
| 02 February 2009 |
The Danish Medicines Agency's assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.
-
Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)
| 19 December 2008 |
The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.
-
Reassessment of reimbursement status for 5 combination products in ATC groups C07, C08 and C09
| 27 November 2008 |
The Danish Medicines Agency has assessed the question of the future reimbursement status for five combination products in ATC groups C07, C08 and C09 on the basis of updated information about prices and consumption of these medicinal products.
-
Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases
| 21 November 2008 |
The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline
-
Reassessment of reimbursement status for medicinal products in ATC group C08CA
| 29 October 2008 |
The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.
-
Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee
| 08 September 2008 |
The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).
-
Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases
| 07 July 2008 |
The Reimbursement Committee's recommendation about the future reimbursement status of medicinal products for the treatment of cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensive drugs) was submitted for consultation on 5 May 2008.
